View in EDS

Tafasitamab plus lenalidomide and R-CHOP versus R-CHOP for first-line treatment of patients with high-risk diffuse large B-cell lymphoma (frontMIND): a global, phase 3, randomised, double-blind, placebo-controlled trial.

Saved in:
Bibliographic Details
Title: Tafasitamab plus lenalidomide and R-CHOP versus R-CHOP for first-line treatment of patients with high-risk diffuse large B-cell lymphoma (frontMIND): a global, phase 3, randomised, double-blind, placebo-controlled trial.
Authors: Lenz G; Department of Medicine A for Hematology, Oncology and Pneumology, University Hospital Münster, Münster, Germany. Electronic address: georg.lenz@ukmuenster.de., Trněný M; First Faculty of Medicine, Charles University, Prague, Czech Republic., Burke JM; Sarah Cannon Research Institute at Rocky Mountain Cancer Centers, Aurora, CO, USA., Nowakowski GS; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Fox CP; School of Medicine, University of Nottingham, and Clinical Haematology, Nottingham University Hospitals NHS Trust, Nottingham, UK., Chiappella A; Fondazione IRCCS Istituto Nazionale dei Tumori, Hematology, Milan, Italy., Duell J; Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany., Jeon YW; Department of Hematology, Yeouido St Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea., Cheah CY; Hollywood Private Hospital and University of Western Australia, Nedlands, WA, Australia., Westin J; MD Anderson Cancer Center, Houston, TX, USA., Ye JZ; American Oncology Network, Vista Oncology Division, Olympia, WA, USA., Caguioa PB; St Luke's Medical Center, Quezon, Philippines., Belada D; Department of Internal Medicine-Haematology, Charles University, Hospital and Faculty of Medicine, Hradec Králové, Czech Republic., Shin HJ; Division of Hematology-Oncology, Department of Internal Medicine, Research Institute of Medical Science, Pusan National University Hospital, Pusan National University School of Medicine, Busan, South Korea., Oh SY; Division of Hematology-Oncology, Department of Internal Medicine, Dong-A University College of Medicine, Busan, South Korea., Amorim S; Department of Hematology and Cellular Therapy, Hôpital Saint Vincent de Paul, Lille, France., Ku M; Department of Haematology, St Vincent's Hospital, University of Melbourne, Melbourne, VIC, Australia., Mocikova H; Department of Hematology, Third Faculty of Medicine, Charles University, and University Hospital Kralovske Vinohrady, Prague, Czech Republic., Jiménez JL; Department of Haematology and Hemotherapy, Hospital Ramón y Cajal, Universidad Alcalá Henares, IRYCIS, Madrid, Spain., Gaidano G; Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont and AOU Maggiore della Carità, Novara, Italy., Rosenwald A; Institute of Pathology, University of Würzburg, Würzburg, Germany., Chiarle R; Division of Diagnostic Haematopathology, IEO European Institute of Oncology IRCCS, Milan, Italy; Department of Molecular Biotechnology and Health Sciences, University of Torino, Turin, Italy., Colucci P; Incyte Corporation, Wilmington, DE, USA., Ioannidis S; Incyte Biosciences International Sàrl, Morges, Switzerland., Cheng L; Incyte Corporation, Wilmington, DE, USA., Vitolo U; Candiolo Cancer Institute, FPO-IRCCS Candiolo, Turin, Italy.
Corporate Authors: frontMIND Study Investigators
Source: Lancet (London, England) [Lancet] 2026 Jun 20; Vol. 407 (10547), pp. 2528-2541. Date of Electronic Publication: 2026 May 30.
Publication Type: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study
Journal Info: Publisher: Elsevier Country of Publication: England NLM ID: 2985213R Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-547X (Electronic) Linking ISSN: 01406736 NLM ISO Abbreviation: Lancet Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 42217458
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Tafasitamab plus lenalidomide and R-CHOP versus R-CHOP for first-line treatment of patients with high-risk diffuse large B-cell lymphoma (frontMIND): a global, phase 3, randomised, double-blind, placebo-controlled trial.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Lenz+G%22">Lenz G</searchLink>; Department of Medicine A for Hematology, Oncology and Pneumology, University Hospital Münster, Münster, Germany. Electronic address: georg.lenz@ukmuenster.de.<br /><searchLink fieldCode="AU" term="%22Trněný+M%22">Trněný M</searchLink>; First Faculty of Medicine, Charles University, Prague, Czech Republic.<br /><searchLink fieldCode="AU" term="%22Burke+JM%22">Burke JM</searchLink>; Sarah Cannon Research Institute at Rocky Mountain Cancer Centers, Aurora, CO, USA.<br /><searchLink fieldCode="AU" term="%22Nowakowski+GS%22">Nowakowski GS</searchLink>; Division of Hematology, Mayo Clinic, Rochester, MN, USA.<br /><searchLink fieldCode="AU" term="%22Fox+CP%22">Fox CP</searchLink>; School of Medicine, University of Nottingham, and Clinical Haematology, Nottingham University Hospitals NHS Trust, Nottingham, UK.<br /><searchLink fieldCode="AU" term="%22Chiappella+A%22">Chiappella A</searchLink>; Fondazione IRCCS Istituto Nazionale dei Tumori, Hematology, Milan, Italy.<br /><searchLink fieldCode="AU" term="%22Duell+J%22">Duell J</searchLink>; Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany.<br /><searchLink fieldCode="AU" term="%22Jeon+YW%22">Jeon YW</searchLink>; Department of Hematology, Yeouido St Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea.<br /><searchLink fieldCode="AU" term="%22Cheah+CY%22">Cheah CY</searchLink>; Hollywood Private Hospital and University of Western Australia, Nedlands, WA, Australia.<br /><searchLink fieldCode="AU" term="%22Westin+J%22">Westin J</searchLink>; MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Ye+JZ%22">Ye JZ</searchLink>; American Oncology Network, Vista Oncology Division, Olympia, WA, USA.<br /><searchLink fieldCode="AU" term="%22Caguioa+PB%22">Caguioa PB</searchLink>; St Luke's Medical Center, Quezon, Philippines.<br /><searchLink fieldCode="AU" term="%22Belada+D%22">Belada D</searchLink>; Department of Internal Medicine-Haematology, Charles University, Hospital and Faculty of Medicine, Hradec Králové, Czech Republic.<br /><searchLink fieldCode="AU" term="%22Shin+HJ%22">Shin HJ</searchLink>; Division of Hematology-Oncology, Department of Internal Medicine, Research Institute of Medical Science, Pusan National University Hospital, Pusan National University School of Medicine, Busan, South Korea.<br /><searchLink fieldCode="AU" term="%22Oh+SY%22">Oh SY</searchLink>; Division of Hematology-Oncology, Department of Internal Medicine, Dong-A University College of Medicine, Busan, South Korea.<br /><searchLink fieldCode="AU" term="%22Amorim+S%22">Amorim S</searchLink>; Department of Hematology and Cellular Therapy, Hôpital Saint Vincent de Paul, Lille, France.<br /><searchLink fieldCode="AU" term="%22Ku+M%22">Ku M</searchLink>; Department of Haematology, St Vincent's Hospital, University of Melbourne, Melbourne, VIC, Australia.<br /><searchLink fieldCode="AU" term="%22Mocikova+H%22">Mocikova H</searchLink>; Department of Hematology, Third Faculty of Medicine, Charles University, and University Hospital Kralovske Vinohrady, Prague, Czech Republic.<br /><searchLink fieldCode="AU" term="%22Jiménez+JL%22">Jiménez JL</searchLink>; Department of Haematology and Hemotherapy, Hospital Ramón y Cajal, Universidad Alcalá Henares, IRYCIS, Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22Gaidano+G%22">Gaidano G</searchLink>; Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont and AOU Maggiore della Carità, Novara, Italy.<br /><searchLink fieldCode="AU" term="%22Rosenwald+A%22">Rosenwald A</searchLink>; Institute of Pathology, University of Würzburg, Würzburg, Germany.<br /><searchLink fieldCode="AU" term="%22Chiarle+R%22">Chiarle R</searchLink>; Division of Diagnostic Haematopathology, IEO European Institute of Oncology IRCCS, Milan, Italy; Department of Molecular Biotechnology and Health Sciences, University of Torino, Turin, Italy.<br /><searchLink fieldCode="AU" term="%22Colucci+P%22">Colucci P</searchLink>; Incyte Corporation, Wilmington, DE, USA.<br /><searchLink fieldCode="AU" term="%22Ioannidis+S%22">Ioannidis S</searchLink>; Incyte Biosciences International Sàrl, Morges, Switzerland.<br /><searchLink fieldCode="AU" term="%22Cheng+L%22">Cheng L</searchLink>; Incyte Corporation, Wilmington, DE, USA.<br /><searchLink fieldCode="AU" term="%22Vitolo+U%22">Vitolo U</searchLink>; Candiolo Cancer Institute, FPO-IRCCS Candiolo, Turin, Italy.
– Name: AuthorCorporate
  Label: Corporate Authors
  Group: Au
  Data: <searchLink fieldCode="CA" term="%22frontMIND+Study+Investigators%22">frontMIND Study Investigators</searchLink>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%222985213R%22">Lancet (London, England)</searchLink> [Lancet] 2026 Jun 20; Vol. 407 (10547), pp. 2528-2541. <i>Date of Electronic Publication: </i>2026 May 30.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier%22">Elsevier </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>2985213R <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1474-547X (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2201406736%22">01406736 </searchLink><i>NLM ISO Abbreviation: </i>Lancet <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=42217458
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/S0140-6736(26)00866-4
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 2528
    Titles:
      – TitleFull: Tafasitamab plus lenalidomide and R-CHOP versus R-CHOP for first-line treatment of patients with high-risk diffuse large B-cell lymphoma (frontMIND): a global, phase 3, randomised, double-blind, placebo-controlled trial.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Lenz G
      – PersonEntity:
          Name:
            NameFull: Trněný M
      – PersonEntity:
          Name:
            NameFull: Burke JM
      – PersonEntity:
          Name:
            NameFull: Nowakowski GS
      – PersonEntity:
          Name:
            NameFull: Fox CP
      – PersonEntity:
          Name:
            NameFull: Chiappella A
      – PersonEntity:
          Name:
            NameFull: Duell J
      – PersonEntity:
          Name:
            NameFull: Jeon YW
      – PersonEntity:
          Name:
            NameFull: Cheah CY
      – PersonEntity:
          Name:
            NameFull: Westin J
      – PersonEntity:
          Name:
            NameFull: Ye JZ
      – PersonEntity:
          Name:
            NameFull: Caguioa PB
      – PersonEntity:
          Name:
            NameFull: Belada D
      – PersonEntity:
          Name:
            NameFull: Shin HJ
      – PersonEntity:
          Name:
            NameFull: Oh SY
      – PersonEntity:
          Name:
            NameFull: Amorim S
      – PersonEntity:
          Name:
            NameFull: Ku M
      – PersonEntity:
          Name:
            NameFull: Mocikova H
      – PersonEntity:
          Name:
            NameFull: Jiménez JL
      – PersonEntity:
          Name:
            NameFull: Gaidano G
      – PersonEntity:
          Name:
            NameFull: Rosenwald A
      – PersonEntity:
          Name:
            NameFull: Chiarle R
      – PersonEntity:
          Name:
            NameFull: Colucci P
      – PersonEntity:
          Name:
            NameFull: Ioannidis S
      – PersonEntity:
          Name:
            NameFull: Cheng L
      – PersonEntity:
          Name:
            NameFull: Vitolo U
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 20
              M: 06
              Text: 2026 Jun 20
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 1474-547X
          Numbering:
            – Type: volume
              Value: 407
            – Type: issue
              Value: 10547
          Titles:
            – TitleFull: Lancet (London, England)
              Type: main
ResultId 1